首页 > 市场调查报告书 > 製药

精神疾病

市场调查报告书

商品编码

1544631

精神分裂症药物市场、机会、成长动力、产业趋势分析与预测，2024-2032

Schizophrenia Drugs Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月09日 | 出版商:

Global Market Insights Inc. | 英文 189 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2024年至2032年，全球精神分裂症药物市场的复合年增长率将达到7.1%，这归因于精神分裂症盛行率的增加，这需要有效的治疗解决方案。药理学研究的进步导致了新型抗精神病药物的开发，这些药物提高了疗效并减少了副作用，使治疗更易于管理并提高了患者的依从性。举个例子，2023年4月，CHEPLAPHARM宣布从礼来公司收购Zyprexa(R)。该交易包括 Zyprexa(R) 及其各种形式的全球权利，从而增强了 CHEPLAPHARM 的精神分裂症和双相情感障碍治疗产品组合。

此外，人们对精神健康状况的认识不断提高，并消除了对其的污名化，导致诊断率提高，对治疗方案的需求也随之增加。医疗保健支出和精神健康基础设施投资的增加透过促进创新疗法和综合护理的获得进一步支持市场扩张。

精神分裂症药物市场根据治疗类别、类型、治疗、配销通路和地区进行分类。

从 2024 年到 2032 年，第三代抗精神病药物领域将保持显着的需求，因为与早期类别的抗精神病药物相比，它们具有卓越的疗效和有利的副作用。这些较新的药物也称为非典型抗精神病药，具有显着的优势，例如降低锥体外症状的风险以及降低体重增加和代谢问题的发生率。他们能够更有效地管理精神分裂症的阳性和阴性症状，再加上患者依从性和生活品质的提高，正在引领精神分裂症药物的采用。

到 2032 年，青少年型精神分裂症部分将占据显着的市场份额，因为其独特且往往严重的症状，需要专门的治疗方法。青少年型精神分裂症的特征是行为失调、情绪反应不当和认知功能受损，为治疗带来了明显的挑战。对解决这些特定症状的有效药物的需求正在推动新药物疗法的开发和采用，从而有助于市场扩张。

受精神分裂症高盛行率和对有效治疗解决方案需求增加的推动，北美精神分裂症药物市场将在 2024 年至 2032 年间显着增长。先进的医疗基础设施和广泛的医疗服务有利于早期诊断和治疗，进一步支持市场成长。此外，提高认识并减少对精神健康状况的耻辱会鼓励更多人寻求治疗，从而导致北美地区对精神分裂症药物的需求不断增长。

产业生态系统分析
产业影响力
- 成长动力
  - 精神分裂症盛行率增加
  - 药物输送系统的进步
  - 政府措施和支持
- 产业陷阱与挑战
  - 药物的副作用
  - 严格的监管场景
成长潜力分析
监管环境
技术景观
- 核心技术
- 邻近技术
未来市场趋势
管道分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按治疗类别，2021 - 2032 年

主要趋势
第二代抗精神病药
第三代抗精神病药
其他治疗类

第 6 章：市场估计与预测：按类型，2021 - 2032

主要趋势
偏执型精神分裂症
青少年型精神分裂症
紧张性精神分裂症
未分化精神分裂症
其他类型

第 7 章：市场估计与预测：按处理方式，2021 - 2032

主要趋势
口服
可注射

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

主要趋势
医院药房
零售药局
网路药局

第 9 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

AbbVie Inc.
Alkermes Public Limited Company
AstraZeneca PLC
Bristol-Myers Squibb Company
Eli Lilly and Company
H. Lundbeck A/S
Intra-Cellular Therapies, Inc.
Johnson and Johnson
Otsuka Pharmaceutical Co., Ltd.
Pfizer Inc.
Recordati Industria Chimica e Farmaceutica S.p.A
SUMITOMO PHARMA CO., LTD
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Limited
Vanda Pharmaceuticals Inc.

简介目录

Product Code: 10166

Global Schizophrenia Drugs Market will record a 7.1% CAGR from 2024 to 2032, attributed to an increase in the prevalence of schizophrenia, which necessitates effective treatment solutions. Advances in pharmacological research have led to the development of novel antipsychotic medications with improved efficacy and reduced side effects, making treatment more manageable and enhancing patient adherence. Citing an instance, in April 2023, CHEPLAPHARM announced the acquisition of Zyprexa(R) from Eli Lilly. The deal includes global rights to Zyprexa(R) and its various forms, enhancing CHEPLAPHARM's portfolio for schizophrenia and bipolar disorders treatment.

Additionally, growing awareness and de-stigmatization of mental health conditions are leading to higher diagnosis rates and greater demand for treatment options. The rise in healthcare expenditure and investment in mental health infrastructure further supports market expansion by facilitating access to innovative therapies and comprehensive care.

The schizophrenia drugs market is sorted based on therapeutic class, type, treatment, distribution channel, and region.

The third-generation antipsychotics segment will retain a notable demand from 2024 through 2032, because of their superior efficacy and favorable side effect profile compared to earlier classes of antipsychotics. These newer medications, also known as atypical antipsychotics, offer significant advantages such as reduced risk of extrapyramidal symptoms and lower incidence of weight gain and metabolic issues. Their ability to manage both positive and negative symptoms of schizophrenia more effectively, combined with improved patient adherence and quality of life, is ushering in the adoption of schizophrenia drugs.

By 2032, the hebephrenic schizophrenia segment will hold a remarkable market share, due to its unique and often severe symptomatology, which necessitates specialized treatment approaches. Characterized by disorganized behavior, inappropriate emotional responses, and impaired cognitive function, hebephrenic schizophrenia presents distinct challenges in management. The need for effective medications that address these specific symptoms is fueling the development and adoption of new drug therapies, aiding the market expansion.

North America schizophrenia drugs market will register a noteworthy growth rate between 2024 and 2032, propelled by a high prevalence of schizophrenia and amplified demand for effective treatment solutions. Advanced healthcare infrastructure and widespread access to medical services facilitate early diagnosis and treatment, further supporting market growth. Additionally, increasing awareness and reducing stigma around mental health conditions encourage more individuals to seek treatment, contributing to the rising demand for schizophrenia drugs across North America.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of schizophrenia
  - 3.2.1.2 Advancements in drug delivery systems
  - 3.2.1.3 Government initiatives and support
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Side effects of drugs
  - 3.2.2.2 Stringent regulatory scenario
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Future market trends
3.7 Pipeline analysis
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Therapeutic Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Second generation antipsychotics
5.3 Third generation antipsychotics
5.4 Other therapeutic classes

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Paranoid schizophrenia
6.3 Hebephrenic schizophrenia
6.4 Catatonic schizophrenia
6.5 Undifferentiated schizophrenia
6.6 Other types

Chapter 7 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Injectable

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa